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4:30 
~ Coronary Slanting During Acute Myocardial 
Infarction. Results From the Stent Without 
Coumadln French Registry 
Thierry Lef~we, Made-claude Modce, Ga~tan Karditon, Pierre Aubry, 
Gilles Zemour, Bernard Valeix. ICVPat~s Sud, France 
lntra coronary Thmmbus and acute M.! were till recently a confmind'¢ation to
coronary stenting, Ticlopidine has dramaticaly decreased the dsk of subacute 
thrombosis after stenting to the point that some patients were stentud dudng 
acute M.I in the registry. To evaluate the outcome of those Pts a retrospective 
analysis was conducted. 
All Pts (2901) included in the registry from March 1991-1995 had 11clo- 
ptdtno (250-500 rag/day) the day of PTCA for 1 month, aspirin (100-250 
mg/dey) for > 6 months and low molecular weight hepadn (antiXa 0.5-1) for 
I month in phase II (237 Pts), 15 days in phase III (521 Pts), 7 days in phase 
IV (960 Pts) and not in phase V (1183 Pts). 
Only 85 Pts (2.9%) had primary' or rescue PTCA with stenting dudng acute 
M,I (age 59.8 =E 11.3 years, 11% female). Indication for stenting was respec- 
tively: subop'-;mal result (26%), non occlusive dissection (28%), occlusive 
dissection (11%) and de novo lesion (35%). Stented coronary ~rtedes were 
LAD: 33%, RCA: 49%, Cx: 9%, L,M: 2% and Bypass: 5%, Palmaz-Schatz 
stsnfs were used in 74% of cases, AVE stents in 24% and other stents in 
2%. One stent was used in 80% of cases and > 1 in 20%). Balloon used for 
stentlng was 3.38 ± 0.46 mm in diameter with an inflation pressure of 123 :l: 
3.0 arm. No vascular complication, stroke or emergency CA6G occured at 1 
month follow-up. Subacute desure occurecl in 1.~,~ of cases, elective CABG 
in 1.2%, acute M,I in 2.4% and death in 5.9%. The composite nd-point of 
subacute closure, acute M.I., CABG and death occlJred in 8,2%. 
In conclusion: coronary stenting is leasable in acute M.I with a low rate 
of subacute closure. Randomised study are necessary to evaluate mid-term 
outcome compared to POBA. 
4:45 
~ Intrscorenary Stenttng In the Setting of Myocardial 
Infarction 
Michel R. Le May, Madno Labinez, Rob S,B. Beanlands, Louise A. LaramC~e, 
Ed O'Bden, Jear~Frencois Marquis, William L. Williams, Khalid AI-Sadoon, 
Richard F. Davies, Sharon Ann Keams, Helen L. Johansen, Lyall 
A. Higginson. Ottawa Heart Institute, Ottawa, Ontado, Canada 
Data on feasibility, safety and clinical OUtcome of intmcaronary stenting (ICS) 
in the setting of MI are limited. Palmaz-$chatz stents were inserted in 49 
patients admitted with acute MI between 01/94 and 05/95. Group A, (n = 23) 
were stented early, day 0 to 7 of MI and Group B, (n = 26~ were stentsd late, 
8-25 days post MI. Demographics in the two groups were similar except hat 
all patients with cardiogenic shock (n = 4) were in Group A (P < 0.05), Only the 
infarct-related artery was stented. Quantitative measurements were obtained 
on the target lesion before and after ICS Between Group A and Group B them 
was no difference in minimal luminal diameter (MLD) or % diameter stenosis 
(DS) before or after ICS. In Group A, MLD increased from 0.43 -~ 0.36 to 
2 58 :E 0.47 mm (P < 0,0001); in Group B, MLD increased from 0.55 :i: 0.33 
t ~} 2,61 :E 0.40 mm (P < 0.0001), Percentage DS decreased in Group A from 
83 ± 14 to 15 piusmn; 13 (P < 0.0001) and in Group B front 79:1:12 to 12 
:E 12 (P < 0.000t). Visible thrembus was present in 39% of Group A and in 
23% of Group B before ICS (P = 0.35) but was not associated with adverse 
outcome. Only one patient had visible thrembus post ICS which resolved 
with intracoronary urokinase. During hosptiatization, o patient experienced 
recurrent MI or required CABG; in Group A, 2 patients required repeat PTCA 
and one patient died. There were no events in Group B. At follow-up of 5.9 
4.0 months, ~ti Group A patients were free of recurrent MI, repeat PTCA, 
CABG, and death; 80% were free of angina. In Group B patients followed to 
7.3 :t: 4.5 months, there ware 2 deaths; 3 patients required repeat PTCA and 
no patient required CABG; 71% of the remaining patients were free of angina. 
Conclusion: IGS in the setting of MI is associated with excellent imme- 
diate angiogrsphic sucoe~ and favoumble clinical outcome, Intmcoronary 
thrombus does not preclude stenting in patients with ML 
5:00 
~ Ele~lve Stent Implantation In Acute Coronary 
Syndromes Induced by Thrombus Containing 
Lesions 
Migual Romere, Alfonso Medina, Jos~ Su~zrez de Lezo, Manuel Pan, 
Endque Hem~mdez, Jss~ Segura, Francisco MellOn, DJordje Pavlovic, Jes~ 
R. Ortega. Reina Sofia Hospital, Universfty of C~rdoba and Pine Hospital, 
University of Las Patinas, Spain 
The presence el angi0graphio thrombus in coronary lesions has been Identi- 
fled as a dsk factor for adverse events during percutaneous revascuiarization; 
the use of stents could theoretically be contraindicated because of the intrin. 
sic thmmbegenicity of the stent-wims. We postulated that the achievement 
of the highest lumen diameter in this setting, could overcome such an ad- 
verse thrembegenio combination. From a total of 812 patients (pts) treated 
hy stent implantation, we selected for study 87 having coronary lesions with 
angiographtc evidence, of intraiominal filling defects, and rest angina within 
the last 48 hours. At cardiac catheterization the responsible artery was totally 
occluded in 41 pts and severely stenoseo in 46 (mean 82 :E 12%). Be o 
fore treatment or a.qer ecanalizetion, intraluminal thrembus was always evi- 
denced. A etent was ~¢Janted trying to achieve an optimal umen size. After 
deployment the residual stenoals was 4 :l: 9%. The filling defect decreased, 
but persisted in 10 and disappeared in 77, All pts became asymptomatic; 
38 of them received conventional antithrembotio regimen (iv-hepadn and 
coumadin) and 30 were treated by low-molecular-weight heparin, t~opidine 
and aspirin; 3 patients had a myocardial infarction; no other major compli- 
cations occurred; 41 patients (47%) were anpographically reevaluated at a 
mean of 7 ~ 4 months; 12 of them (29°/,,) showe'~ rastenesis. 
Conclusions: Elective stent treatment may b~ ~f benefit in unstable pa- 
tients with thrembus containing slenosis. The thrL. Lbegenic ombination of 
preexistir~ threntbu~, a.-.,'J .Petal, paradoxically, do~ ~ ;'~t preclude a good 
outcome. 
5:15 
.Prel!m!na~. Experience With the POSSIS Coronary 
Anglo~et Hneolytic i nromoectomy Catheter in the 
VEGAS I Pilot Study 
Stephen R, Ramea, Richard E. Kuntz, Richard A. Schatz, Joseph 
P. Carrozza, Jeffrey J. Pupma. Alyce S. Lenoue, Cynthia Senerchia, Robert 
C. $ioler, Kaion K.L. He, Donald S. Balm. Ochsner Hospital, New Orleans. 
LA; Beth Israel Hospital, Boston, MA 
The curre~ peroutaneous treatment of thrombotic obetructians in native 
coronary attefle~ (NC) or saphenous vein grafts (SVG) is limited by dis- 
tal embolizalion and incomplete evacuation or dissolution in many cases. 
The POSSIS AngioJet catheter removes intravasculer thrombus bodies by 
rbeolytio thmmbectomy: a Venturi effect created by precisely directed high 
pressure saline jets located at the tip of the 5 French over-the-wire catheter, 
The VEGAS I Pilot study ,,~ill evaluate the AngioJet in saphenous vein grafts 
and native coronary arteries. In 15 lesions treated in the first 15 patients, 8 
were in SVG and 7 in NC (including 3 patients with acute myocardial infarc- 
tion). Thrombotic appearing obstructions were successfully reduced in 14 of 
the 15 (93%) cases with AngioJet alone from 91 :E 18% diameter stenssis 
to 44 :t: 22% (visual estimates). In the one unsucces~l case, the undeity. 
ing stsnosis was concluded to be non-thmmbetic. In all cases, subsequent 
treatment included balloon angiopiasty in 2, directional atherectomy in 1, and 
Palrnaz-Sctlatz stenttng in 12, for final residual diameter stenesis of 5 ± 12%. 
Complications included transient heart block ~.~quiring temporary pacing in 
6, and tt'ansient "no inflow" in 2. 
Condus/on: 1) The AngioJet removes intravascuiar thmml~s in SVGs 
and native coronary arteries with high success and low complication rates. 2) 
Successful thrembus removal appear~ to prepare the vessel for subsequent 
safe and uncomplicated treatment by stenting, balloon angiopiasty, or direc- 
tional alhamcton~,. 3) The final results of this 60 patient pilot study should 
provide the background experience for the phase 2 randomized trial, VEGAS 
II. 
Neurohormonal Factors in Heart Failure 
Monday, March 25, 1996, 4:00 p.m.--5:30 p.m. 
Orange County Convention Center, Room 208 
4:O0 
1723-1 ~ The Relative Value of the Natrlumtio Peptides as 
Markers for Detecting Abnormal Ventricular 
Structure and Function 
Kazuh[re Yamamoto, John C, Bumett, Jr., Michihisa Jougasaki, 
Yoshihiko Sa-ito, Kazuwa Nakao, David R. Holmes, Jr., Margaret 
M, Redfield. Mayo Clinic, Rochester, MN 
Previous studies have suggested that brain and C- and N-terminal atrial 
natriuretic peptides (BNP. C-ANR N.ANP) may have diagnostic utility in the 
detection of LV hypertrophy (LVH) or LV dysfunction. The current study was 
designed to Jetennine the relative utility of measuring serum levels of BNR 
C.ANP or N-ANP to detect LVH or systolic or diastolic dysfunction. BNP 
(Shloncgi), C-ANP (Peninsula) and N-ANP (Phoenix) were determined by 
redioimmunsassay, ejection fraction (EF) and LV mass index were measured 
!iiiiii!iiiii! 
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by echocardiogrephy and the time constant of LV relaxation (Tau) was derived 
from the LV pressure to assess diastolic function in 94 consecutive patients 
with suspected cardiac disease. The sensitivity and specificity of optimal 
values of each papttde !or detecting abe l  LV function or LVH were: 
EF < 45% sensitiv~: BNP (83%) > C-ANP (79%) > N-ANP (67%) 
specific~y: BNP (81%) > C-ANP (67%) > N-ANP (63%) 
Tau > 55 ms sensitivity; BNP (85%) > N-ANP (70%) > C-ANP (60%) 
specificity: BNP t74%) :- C-ANP (65%) > N-ANP {81%) 
LV mass index > 120 g/m 2 sensitivity: BNP (81%) > N-ANP (73%) > C-ANP (69%) 
specificity: BNP (90%) :. N-ANP (79=/.) > C-ANP (67%) 
By recaiver-operator-charactadstic (ROC) analysis, BNP was significantly 
more sensitive and specific than C-ANP or N.ANP for dstecting abnormal 
ER Tau or LV mass index with an ROC value of 0.85, 0.8?,, and 0.91 respac- 
tive~y. Sensitivity for detecting abnormal LV structure or function employing 
a "natfluretic peptido penal ~ with an abnormal ~NP orC-ANP or N-ANP ax- 
ceeded that of BNP alone and was for EF < 4S% (96%), Tau < 55 ms (90%) 
and LV mass index > 120 g/m 2 (06%). Conclusions:BNP is the single best 
test to detect abnormal systolic and diastolic function and LVH in patients 
with suspected cardiac disease. A "natriuretic peptide panel" has very high 
sensitivity and may be a useful screening test in some populations. 
4:15 
~ Attenuation B.type Peptt=de (BNP) of Natrluretic 
Secreted From an Infarcted Segment Remssnts the 
Process of  Left Vantricular Remodeling After 
Myocardial Infarction 
Atsusht Hirayama, Fuminobu lshikura, Neeyu~ Misaki, Hisakasu Fuji, 
Takayoshi Adechi, Yashuhlko Seksta, Kazuhisa Kodama, Osaka Police 
Hospital, Osaka, Japan 
As B-type natduratic peptide (BNP) is known tO be a marker for ventdcu- 
lar hypertrophy and/or dilatation, its measurement at the infarcted segment 
might be useful to evaluate infarct expansion after the onset of myocardial 
infarction (M1). Seventy five patients of first antedor MI without any car- 
diac event since their first attack were subjected to cardiac catheterization 
performed 18 ± 15 months (range 1 to 45 months) after the onset of MI. 
Hemodynamic parameters, left ventdcular (LV) volumes and function on LV 
graphy and plasma BNP concentration (pg/ml) of aortic root (Ao) and anterior 
intervantdcular vein (AIV) were measured by radioimmuncessay. The differ- 
once of plasma BNP concentration between AIV and Aa {AIV-Ao), which 
reflect BNP secreted from the infarct segment, had significant correlations 
with EDVI (r = 0.67, p = 0.001), ESVI (r = 0,65, p = 0.001), EF (r = 0.71, p = 
0.001), LVEDP (r = 0.53, p = 0.003), and the duration from the onset of MI to 
the cardiac catheterization (r= -0.75, p = 0.001). By multivariate analysis, 
however, EDVI (p = 0.003) and the duration from the onset of MI (p = 0.0021 )
among the variables were picked up as significant factors determining the 
plasma concentration of BNP at AIV-Ao. These results indicated that BNP 
released from the infarcted segment is enhanced by the ventdcular dilatation 
and attenuated in the course of time after ML These results suggested the 
secretion of BNP at the infarcted segment w~c stimulated by the infarct ex- 
pansion at the eady pedod after MI but decrJased with the accomplishment 
of expansion dudng the late period. 
In conclusion, BNP secreted from the infarct segment represent he pro* 
cess of LV remodeling after MI. 
4:30 
1723-3 ~ Repetitive Bolus Administration of Brain Natriuratlc 
Peptlde Reduces Cardiac Filling Pressures in 
Human Heart Failure 
Robert J, Cody, for the Natrecor hBNP Multicenter Bolus Trial. Ohio State 
University, Columbus, Ohio 
Endogenous natduretic poptides (NP) produce vesodilallon, in response to 
the myocardial remodeling of congestive heart failure (CHF). individual NP 
sequences of single gone origin, confer distinct cardiovascular character- 
istics. In this multicenter trial, we evaluated the effect of repetitive bolus 
administration of brain nstriuretic peptide (hBNP) in patients (pts) with CHF, 
during hemodynamic evaluation. 28 of 29 pts were NYHA II1 or IV, and all 
had EF < 30%. hBNP was given as 5 #g Q4H (7 pts), 10 p.g Q4H (6 
pts), 10 #g Q6H (6 pts), with placebo groups for Q4H (6 tots) and QaH 
(4 pts) tnten/ais. For each treatment inten~i, pts received repetitive doses 
over 24 hrs. Placebo groups were pooled for statistical analysis, considering 
betwaen4wlthin-group differences, and dosage hierarchy, p < 0.05(') being 
significant. Pulmonary wedge (PWP) and dght atrial (RAP) pressures: 
PWp (mmH9) 
Baseline 
hBNP + 0.5 hrs 
hBNP + 1 hr8 
hBNP + 2 hm 
RAP (mmHg) 
Basins 
hBNP + 0,S hrS 
hBNP + 1 hrs 
hBNP ÷ 2 hrs 
Placebo 5EgQ4H ............. !0/~g,Q4H 10/~g Q6 H 
27=7 2S±6 ~±6 27~5 
26:~9 ta~:P 19:1:8 • 12:EP 
27±8 1S±6* 20~7" 13:~6" 
26:b5 18±8' 21 ~-9 ~ 16 d:6" 
15-;-8 13±8 12~4 12-1-7 
15±7 10~8" 84-p 7:~5" 
16±7 9±9" 8±6 '~ 6±5" 
14d:a 10~8" 7 -;- 4'* 7:~5- 
At the common time point of 12 hours, PWP (15 4. 5) and RAP (4 :t: 
5,) were p < 0,05 for the 10 #g Q4H interval, With the final bolus In each 
group, persistent response of PWP and RAP indicated no tachyphylaxis. 
Changes in cardiac index and system~ resistance were concordant, canals. 
tent with vasedilation. In human CHF, exogenous hBNP improves cardiac 
filling pressures in the setting of vasodilation, sugge -3ting preserved hamody- 
namic responsiveness of the "type A" NP re,~ptor, wl~tle reducing the atdai 
tension stimulus for endogenous NP release. 
4:45 
Exhaled Nitric Oxide as a Measure of Response to 
Therapy in Patients With Heart Failure 
Joshua M. Hare, Anthony R Massaro, Jeffrey M, Drezen, Wilson S. Colucoi. 
Bn'gham and Women's Hospital, Boston, MA 
Endogenous nitric oxide (NO) can be detected in exhaled air and increases 
with exercise and L-arginine administration, possibly reflecting vascular e- 
lease, We hypothesized that exhaled NO would be elevated in patients with 
heart failure (HF) as a compensatory cimulatory mechanism, and would de. 
crease as hemodynamtcs improved with vasedilator and diuretic therapy. 
Chemilumineeanca was used to measure mean mixed expil~l NO content 
of a vital capacity breath in patients with HF (n = 5) and matched controls (n 
= 5) dudng inhalation of NO-free air. Exhaled NO was higher in HF than in 
controls (8.4 :E 3.5 vs. 6.5 :t: 2.4 ppb, p < 0,04). Serial measurements were 
made over of period of therapy (7,3 4- 6 dayS) with sodium nitroprusstde 
(SNP) and diuresis dudng monitoring of pulmonary artedal pressures and 
cardlec output in 7 additional patients with HF breathing room air. 
Pro-therapy SNP for 2 hrs .  Post-therapy 
NO (ppb) 20.4 ~: 6.2 22.8 :b 4.6 11.2 "~ 1.2' 
PVR (dyne-sec-cm-5) 356 ~- 47 287 ± 63 147 ~ 32" 
co (U~n) 3 ~: 0.3 4.64 =~ 0.9 4.8 ± 0.3t" 
PCWP (mmHg) 31 ~: 3 27 :E 2 21 :E 71" 
*p < 0,05 vs. baseline and SNP, tp < 0.01 vs. baseline 
HF therapy improves hemedynamics and is as,~oclated with reductions 
in exhaled NO concentrations. Thus, elevations in exhaled NO may reflect 
a compensatory cimulatory mechanism in HI=, and exhaled NO may be an 
easily obtainable and quantifiable measure of clinical response to therapy in 
HR 
5:00 
~ Medulatlon of Tumor Necrosis Factor o~ in 
Advanced Heart Failure With Cachexla Is 
Associated Wilh Anabol lc Effects 
Richard V. Mtisni, Stefan Endres, Mandeep R, Mehra, Julia Cook, 
Andreas Eigler0 Frank W. Smart, Cad J. Lavla, Joseph R Murgo, Hector 
O. Vanfura. Ochsner Clinic, New Orleans. LA 
Tumor Necrosis Factor (TNF~) has catabolic effects which produce cachexia 
in laboratory animals and humans. Indeed, patients with advanced heart 
failure (aHF) who demonstrate elevated levels of TNFc< often suffer from 
cachexla, a finding characterized by reduced body ~'at. The purpose of this 
double blind, randomized, placebo-controlled study was to evaluate the im- 
pact of modulation of TNF= synthesis on alterations in body fat Indlces 
using n-3 fatty acids. 14 patients with aHF were randomly allocated to ac- 
tive treatment (n.3 fatty adds, 6.4 gins/d; n = 7) vs. t~ocaloric placebo (n 
= 7). TNF= production at baseline and after 18 weeks was assessed using 
lipopolysaccadde monocyte stimulation. 
t.TNF~ synthesis 4% Body Fat 
n-3 Fatty Acids -59% +9.5% 
Placebo +44% -4.2=/=, 
Regression analysis revealed that &TNF~ was inversely and significantly 
correlated with z~% body fat (r value = 0.60, p = 0.02). Conclusions: 1) 
N-3 fatty acid supplementation in aHF results in significant reductions in 
